Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0IFK.L Stock Summary
Top 10 Correlated ETFs
0IFK.L
In the News
0IFK.L Financial details
Company Rating
Sell
Market Cap
516.25M
Income
-153.22M
Revenue
78.12M
Book val./share
4.27
Cash/share
3.95
Dividend
-
Dividend %
-
Employees
265
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-3.86
Forward P/E
-
PEG
1.07
P/S
30.6
P/B
2.09
P/C
1.44
P/FCF
-4.82
Quick Ratio
6.01
Current Ratio
6.12
Debt / Equity
0.03
LT Debt / Equity
-
-
-
EPS (TTM)
-2.05
EPS next Y
-
EPS next Q
-
EPS this Y
-37.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.5%
Revenue last 5Y
30.64%
Revenue Q/Q
1025.36%
EPS Q/Q
-58.18%
-
-
-
-
SMA20
-24.47%
SMA50
-13.36%
SMA100
-27.87%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-54%
ROC
-0.47%
Gross Margin
-295%
Oper. Margin
-848%
Profit Margin
-793%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.07-11.79
52W High
-48.18%
52W Low
-5%
RSI
25.77
Rel Volume
0.18
Avg Volume
5.91K
Volume
1.05K
Perf Week
-15.68%
Perf Month
-43.68%
Perf Quarter
-9.24%
Perf Half Y
-21.7%
-
-
-
-
Beta
2.018
-
-
Volatility
0.39%, 0.99%
Prev Close
-4.2%
Price
5.7
Change
-3.39%
0IFK.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.41 | 1.55 | 0.38 | 0.29 | 1.03 | |
Net income per share | -2.68 | -1.98 | -2.85 | -3.21 | -2.02 | |
Operating cash flow per share | -0.81 | -3.07 | -2.42 | -2.58 | -1.74 | |
Free cash flow per share | -0.94 | -3.19 | -2.54 | -2.64 | -1.8 | |
Cash per share | 9.15 | 6.86 | 7.39 | 5.01 | 4.25 | |
Book value per share | 5.25 | 6.72 | 8.19 | 5.25 | 4.6 | |
Tangible book value per share | 5.25 | 6.72 | 8.19 | 5.25 | 4.6 | |
Share holders equity per share | 5.25 | 6.72 | 8.19 | 5.25 | 4.6 | |
Interest debt per share | 0.12 | 0.12 | 0.15 | 0.16 | 0.16 | |
Market cap | 993.02M | 1.16B | 1.34B | 591.55M | 780.17M | |
Enterprise value | 783.92M | 1.05B | 1.17B | 493.97M | 693.05M | |
P/E ratio | -7.42 | -10.04 | -6.98 | -2.68 | -5.09 | |
Price to sales ratio | 48.37 | 12.83 | 52.59 | 30.01 | 9.99 | |
POCF ratio | -24.42 | -6.47 | -8.2 | -3.34 | -5.9 | |
PFCF ratio | -21.2 | -6.23 | -7.82 | -3.26 | -5.7 | |
P/B Ratio | 3.78 | 2.96 | 2.43 | 1.64 | 2.23 | |
PTB ratio | 3.78 | 2.96 | 2.43 | 1.64 | 2.23 | |
EV to sales | 38.18 | 11.58 | 45.66 | 25.06 | 8.87 | |
Enterprise value over EBITDA | -5.68 | -8.03 | -6.2 | -2.25 | -4.25 | |
EV to operating cash flow | -19.28 | -5.84 | -7.12 | -2.79 | -5.24 | |
EV to free cash flow | -16.74 | -5.62 | -6.79 | -2.72 | -5.06 | |
Earnings yield | -0.13 | -0.1 | -0.14 | -0.37 | -0.2 | |
Free cash flow yield | -0.05 | -0.16 | -0.13 | -0.31 | -0.18 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Debt to assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
Net debt to EBITDA | 1.51 | 0.87 | 0.94 | 0.44 | 0.53 | |
Current ratio | 7.74 | 7.2 | 10.82 | 5.94 | 5.39 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.3 | 1.55 | 0.85 | 0.8 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.14 | 0.74 | 2.98 | 3.59 | 0 | |
Research and developement to revenue | 4.58 | 1.7 | 5.38 | 8.55 | 2.2 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.15 | 0.04 | 0.05 | 0.02 | 0.04 | |
Capex to revenue | -0.3 | -0.08 | -0.31 | -0.21 | -0.06 | |
Capex to depreciation | -2.18 | -1.81 | -1.58 | -0.65 | -0.78 | |
Stock based compensation to revenue | 1.33 | 0.26 | 1.7 | 1.49 | 0 | |
Graham number | 17.78 | 17.29 | 22.9 | 19.48 | 14.44 | |
ROIC | -0.48 | -0.32 | -0.33 | -0.56 | -0.44 | |
Return on tangible assets | -0.26 | -0.2 | -0.28 | -0.43 | -0.31 | |
Graham Net | 4.22 | 3.88 | 5.56 | 2.83 | 2.38 | |
Working capital | 403.88M | 360.88M | 460.43M | 296.64M | 277.61M | |
Tangible asset value | 262.44M | 393.59M | 553.64M | 360.68M | 349.1M | |
Net current asset value | 217.4M | 240.07M | 383.47M | 203.11M | 190.77M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Average receivables | 224K | 3.23M | 3.16M | 2.71M | 7.67M | |
Average payables | 5.59M | 6.13M | 5.73M | 7.28M | 8.89M | |
Average inventory | 0.5 | 0.5 | 1 | 0.5 | 0 | |
Days sales outstanding | 7.43 | 24.33 | 3.82 | 95.27 | 47.59 | |
Days payables outstanding | 22.01 | 14.8 | 364.78 | 547.82 | 497.72 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 49.12 | 15 | 95.67 | 3.83 | 7.67 | |
Payables turnover | 16.58 | 24.66 | 1 | 0.67 | 0.73 | |
Inventory turnover | 0 | 158M | 5.05M | 0 | 0 | |
ROE | -0.51 | -0.29 | -0.35 | -0.61 | -0.44 | |
Capex per share | -0.12 | -0.12 | -0.12 | -0.06 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.1 | 0.14 | 0.04 | 0.07 | 0.73 | |
Net income per share | -0.88 | -0.71 | -0.56 | -0.55 | -0.23 | |
Operating cash flow per share | -0.61 | -0.52 | -0.54 | -0.43 | -0.27 | |
Free cash flow per share | -0.62 | -0.55 | -0.56 | -0.44 | -0.29 | |
Cash per share | 5 | 4.62 | 6.05 | 4.28 | 3.95 | |
Book value per share | 5.24 | 4.61 | 5.6 | 4.41 | 4.27 | |
Tangible book value per share | 5.24 | 4.61 | 5.6 | 4.41 | 4.27 | |
Share holders equity per share | 5.24 | 4.61 | 5.6 | 4.41 | 4.27 | |
Interest debt per share | 0.16 | 0.12 | 0.14 | 0.12 | 0.15 | |
Market cap | 592.65M | 504.7M | 591M | 636.04M | 839.17M | |
Enterprise value | 495.08M | 412.81M | 407.37M | 588.11M | 752.05M | |
P/E ratio | -2.44 | -2.57 | -3.67 | -3.53 | -11.12 | |
Price to sales ratio | 90.68 | 51.23 | 204.71 | 119.2 | 13.97 | |
POCF ratio | -14.02 | -14.11 | -15.27 | -17.94 | -37.73 | |
PFCF ratio | -13.82 | -13.42 | -14.76 | -17.82 | -35.64 | |
P/B Ratio | 1.64 | 1.59 | 1.48 | 1.76 | 2.4 | |
PTB ratio | 1.64 | 1.59 | 1.48 | 1.76 | 2.4 | |
EV to sales | 75.75 | 41.91 | 141.1 | 110.22 | 12.52 | |
Enterprise value over EBITDA | -8 | -8.35 | -9.57 | -12.09 | -33.43 | |
EV to operating cash flow | -11.71 | -11.54 | -10.52 | -16.59 | -33.82 | |
EV to free cash flow | -11.54 | -10.98 | -10.17 | -16.47 | -31.94 | |
Earnings yield | -0.1 | -0.1 | -0.07 | -0.07 | -0.02 | |
Free cash flow yield | -0.07 | -0.07 | -0.07 | -0.06 | -0.03 | |
Debt to equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Debt to assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Net debt to EBITDA | 1.58 | 1.86 | 4.32 | 0.99 | 3.87 | |
Current ratio | 5.94 | 5.68 | 8.09 | 6.12 | 5.39 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.7 | 0.73 | 0.96 | 0.79 | 1.18 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.75 | 2.34 | 5.96 | 2.81 | 0 | |
Research and developement to revenue | 7.71 | 3.68 | 9.78 | 7.31 | 1.13 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.05 | 0.03 | 0.01 | 0.06 | |
Capex to revenue | -0.1 | -0.19 | -0.46 | -0.04 | -0.02 | |
Capex to depreciation | -0.4 | -1.19 | -0.87 | -0.16 | -0.89 | |
Stock based compensation to revenue | 0.82 | 0.46 | 1.81 | 0.89 | 0 | |
Graham number | 10.21 | 8.59 | 8.44 | 7.4 | 4.71 | |
ROIC | -0.16 | -0.14 | -0.1 | -0.13 | -0.06 | |
Return on tangible assets | -0.12 | -0.11 | -0.07 | -0.09 | -0.04 | |
Graham Net | 2.83 | 2.5 | 4.09 | 2.54 | 2.21 | |
Working capital | 296.64M | 267.3M | 386.47M | 300M | 277.61M | |
Tangible asset value | 360.68M | 317.47M | 399.92M | 360.46M | 349.1M | |
Net current asset value | 203.11M | 177.83M | 298.94M | 214.42M | 190.77M | |
Invested capital | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Average receivables | 2.63M | 2.69M | 1.26M | 2.35M | 6.3M | |
Average payables | 8.17M | 9.28M | 8.56M | 9.24M | 9.34M | |
Average inventory | 0 | 0 | 0.5 | 0.5 | 0 | |
Days sales outstanding | 70.85 | 2.21 | 71.26 | 40.85 | 15.27 | |
Days payables outstanding | 542.8 | 527.35 | 471.39 | 618.88 | 507.65 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.27 | 40.71 | 1.26 | 2.2 | 5.89 | |
Payables turnover | 0.17 | 0.17 | 0.19 | 0.15 | 0.18 | |
Inventory turnover | 0 | 0 | 1.54M | 0 | 0 | |
ROE | -0.17 | -0.15 | -0.1 | -0.12 | -0.05 | |
Capex per share | -0.01 | -0.03 | -0.02 | 0 | -0.02 |
0IFK.L Frequently Asked Questions
What is Editas Medicine, Inc. stock symbol ?
Editas Medicine, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol 0IFK.L
What is Editas Medicine, Inc. stock quote today ?
Editas Medicine, Inc. stock price is $5.7 today.
Is Editas Medicine, Inc. stock public?
Yes, Editas Medicine, Inc. is a publicly traded company.